Clinical Trial

Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 6, 2026 (before its estimated June 26, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-06; most recent amendment 2026-02-04.
Status change: Not Yet Recruiting → Recruiting 2025-09-24
Trial Details
NCT Number NCT06924606
Lead Sponsor Shanghai Junshi Bioscience Co., Ltd.
Conditions Advanced NSCLC
Enrollment 66 participants
Start Date 2025-07-15
Primary Completion 2026-06-26 (estimated)
Study Completion 2026-06-26 (estimated)
Updated on ClinicalTrials.gov 2026-02-06